SOLTAMOX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Soltamox, and when can generic versions of Soltamox launch?
Soltamox is a drug marketed by Mayne Pharma Commrcl and is included in one NDA.
The generic ingredient in SOLTAMOX is tamoxifen citrate. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the tamoxifen citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Soltamox
A generic version of SOLTAMOX was approved as tamoxifen citrate by ACTAVIS LABS FL INC on February 20th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SOLTAMOX?
- What are the global sales for SOLTAMOX?
- What is Average Wholesale Price for SOLTAMOX?
Summary for SOLTAMOX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Clinical Trials: | 21 |
| Drug Prices: | Drug price information for SOLTAMOX |
| What excipients (inactive ingredients) are in SOLTAMOX? | SOLTAMOX excipients list |
| DailyMed Link: | SOLTAMOX at DailyMed |
Recent Clinical Trials for SOLTAMOX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Eli Lilly and Company | Phase 2 |
| Jose Pablo Leone | Phase 2 |
| Translational Breast Cancer Research Consortium (TBCRC) | Phase 2 |
Pharmacology for SOLTAMOX
| Drug Class | Estrogen Agonist/Antagonist |
| Mechanism of Action | Selective Estrogen Receptor Modulators |
US Patents and Regulatory Information for SOLTAMOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma Commrcl | SOLTAMOX | tamoxifen citrate | SOLUTION;ORAL | 021807-001 | Oct 29, 2005 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SOLTAMOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mayne Pharma Commrcl | SOLTAMOX | tamoxifen citrate | SOLUTION;ORAL | 021807-001 | Oct 29, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SOLTAMOX
See the table below for patents covering SOLTAMOX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 893121 | ⤷ Sign Up | |
| Japan | H1171269 | ORAL LIQUID PHARMACEUTICAL PREPARATION | ⤷ Sign Up |
| Germany | 69804169 | ⤷ Sign Up | |
| Spain | 2174388 | ⤷ Sign Up | |
| Austria | 214269 | ⤷ Sign Up | |
| European Patent Office | 0893121 | Solution liquide de médicament pour administration orale (Oral liquid medicine solution) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
